EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)

Phase 2 Completed 375 enrolled Endo USA Inc., a Keenova Therapeutics Company

RandomizedParallel-groupDouble-blindTreatment

Summary

The study will evaluate the safety, effectiveness, and immunogenicity of EN3835 in the treatment of adult women with Edematous Fibrosclerotic Panniculopathy (Commonly known as Cellulite).

Timeline

Start: 2016-02
Primary completion: 2016-09
Completion: 2016-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Collagenase Clostridium Histolyticum	Protein / enzyme biologic	0.84 mg	—

EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)

Summary

Timeline

Drugs

Indications